Scaling for a New Era: The Rise of Radiopharma

Pluvicto, Lutathera, Pylarify, and Illuccix demonstrated that modern radiopharmaceuticals can achieve commercial success, driving an influx of investment in the field with venture funding and big pharma investments outpacing other modalities. However, aside from a few well-established drug targets, progress has been limited, and the development and commercialization of diagnostic and therapeutic radiopharmaceuticals remain largely disconnected. In addition, radiopharmaceutical manufacturing and logistics remain costly, complex, and prone to failure given just-in-time, on-demand dose delivery; Even a small number of high-profile R&D or customer-facing setbacks could significantly erode the confidence of clinicians, patients, and, ultimately, investors.

With a proven track record supporting global clinical programs and commercial launches, PharmaLogic serves as a leading CDMO and logistics partner for organizations developing next-generation radiopharmaceutical products. In this webinar, PharmaLogic President & CEO Etienne Montagut will provide an overview of this fast-growing modality and why it has the promise of redefining precision medicine. He will also discuss key challenges in development and commercialization of diagnostic and therapeutic radiopharmaceuticals and PharmaLogic’s unique ability to overcome them to achieve success.

Designed for investors, pharmaceutical leaders, and drug developers, this session offers a clear, strategic view of this growth opportunity.

First name

Last name

Company

Job Title

Country

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from Endpoints News and/or the sponsor(s). View how we use your data here.

If you are experiencing problems with your registration, please try the Zoom registration page.

Etienne Montagut

President & CEO, PharmaLogic

Etienne Montagut is a seasoned healthcare executive with more than 25 years of experience leading growth, business transformation, and innovation across the global pharmaceutical sector, including over a decade in radiopharmaceuticals. Before becoming President and Chief Executive Officer of PharmaLogic, Etienne held senior leadership positions at Lantheus, GE Healthcare, and Ipsen, where he built a strong track record of revitalizing businesses and fostering high performance cultures across the U.S., Europe, and Asia Before being appointed CEO, Etienne joined PharmaLogic as President in June 2024. He previously spent six years at Lantheus, where he played a pivotal role in transforming the organization into a mid- cap, high-growth radiopharmaceutical leader with a robust pipeline of diagnostic and therapeutic innovations. During his tenure at GE Healthcare, Etienne led the global radiopharmaceutical business, successfully launching products across multiple continents and reshaping the trajectory of the legacy nuclear medicine portfolio. Etienne began his career at Ipsen, advancing from a field sales representative to key roles in corporate strategy and M&A, giving him a uniquely comprehensive perspective on commercial execution and long-term value creation. Etienne holds an MBA from Imperial College, London, and a Master of Business Intelligence from EGE Paris

Arsalan Arif

Founder & publisher, Endpoints news

Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.